Viking therapeutics aktie

Cookie Einstellungen. Marketing- und Statistik-Cookies kommen nicht zum Einsatz.

Up to The Phase 2 VENTURE trial successfully achieved its primary endpoint and all secondary endpoints, with patients receiving VK demonstrating statistically significant reductions in body weight compared with placebo. Additionally, the study showed VK treatment to be safe and well tolerated with the majority of treatment emergent adverse events TEAEs being categorized as mild or moderate. Patients receiving weekly doses of VK demonstrated statistically significant reductions in mean body weight after 13 weeks, ranging up to Patients receiving VK also demonstrated statistically significant reductions in mean body weight relative to placebo, ranging up to Statistically significant differences compared to both baseline and placebo were observed for all doses starting at Week one and continuing throughout the week treatment period. Reductions in body weight were progressive through the course of the study, with no plateau observed for weight loss at 13 weeks.

Viking therapeutics aktie

.

Kurs: EUR

.

Viking Therapeutics Inc. GLP stands for glucagon-like peptide. All 10 analysts polled by FactSet have a buy or equivalent rating on the stock, even though Viking does not yet have a fully approved product on the market. But analysts led by Akash Tewaria acknowledged the trial data were impressive. Subscribe on Spotify and Apple. Canada Pension Plan, one of the largest in the world, doubled its investment in Apple stock, initiated a position in Alibaba, and bought more Microsoft and Tesla.

Viking therapeutics aktie

All of the shares of common stock to be sold in the proposed offering are to be sold by Viking. The proposed offering is subject to market and other conditions, and there can be no assurance as to whether or when the proposed offering may be completed, or as to the actual size or terms of the proposed offering. Viking currently intends to use the net proceeds from the proposed offering for continued development of its VK, VK and VK programs and for general research and development, working capital and general corporate purposes. The proposed offering is being made pursuant to an automatic shelf registration statement on Form S-3 File No. The securities may be offered only by means of a prospectus and prospectus supplement that form a part of the registration statement. A preliminary prospectus supplement and the accompanying prospectus relating to and describing the terms of the proposed offering will be filed with the SEC and will be available on the SEC's website at www.

Cod black ops 3 zombies

This entry point corresponds to a fair value gap, which adds further conviction to our bearish thesis. Marktkapitalisierung: Mio. The company's clinical programs include VK, a novel, orally available, small molecule selective thyroid hormone receptor beta agonist for the treatment of lipid and metabolic disorders, which is currently being evaluated in a Phase 2b study for the treatment of biopsy-confirmed non-alcoholic steatohepatitis NASH and fibrosis. Sonntag, It also hints at potential future price corrections, which is common after periods of rapid growth. Bestbewertete News. Kurs: 0. Indizes Indexliste. Schulden: 1. Eigner: Placebo-adjusted mean percent change from baseline 4,5. Notwendig Details einblenden.

Conference Call Scheduled for Wednesday, February 7 at p.

Reductions in body weight were progressive through the course of the study, with no plateau observed for weight loss at 13 weeks. The Phase 2 VENTURE trial was a randomized, double-blind, placebo-controlled study intended to evaluate the safety, tolerability, pharmacokinetics, and weight loss efficacy of VK, administered subcutaneously, once weekly. Index: -. Viking disclaims any obligation to update these forward-looking statements except as required by law. Gewinn je Aktie: Nachrichten Nachrichten Nachrichten auf FN. Marktkapitalisierung: The company holds exclusive worldwide rights to a portfolio of five therapeutic programs, including VK and VK, which are based on small molecules licensed from Ligand Pharmaceuticals Incorporated. Alle News. Hier klicken. Additionally, the study showed VK treatment to be safe and well tolerated with the majority of treatment emergent adverse events TEAEs being categorized as mild or moderate. This entry point corresponds to a fair value gap, which adds further conviction to our bearish thesis. Sonstige Technologie. Kursziel: -.